Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Fuggle, N. R. (University of Southampton)
Cooper, Cyrus (University of Oxford)
Harvey, N. C. (University of Southampton)
Al-Daghri, Nasser (King Saud University)
Brandi, Maria Luisa (University Hospital of Florence)
Bruyère, Olivier (WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium)
Cano Sánchez, Antonio (University of Valencia)
Dennison, E. M. (University of Southampton)
Díez Pérez, Adolfo (Institut Hospital del Mar d'Investigacions Mèdiques)
Kaufman, J.-M. (Universitair Ziekenhuis Gent)
Palacios, S. (The Palacios Institute of Women's Health, Madrid)
Prieto-Alhambra, D. (University of Oxford)
Rozenberg, S. (CHU St Pierre, Bruxelles)
Thomas, T. (CHU de Saint-Etienne, France)
Tremollieres, F. (Toulouse University Hospital)
Rizzoli, R. (Hôpitaux Universitaires Genève)
Kanis, John A (Australian Catholic University)
Reginster, Jean-Yves (King Saud University)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteoporosis medications. These are presented in this narrative review. Calcium supplementation could theoretically cause atheroma formation via calcium deposition, and in one study was found to be associated with myocardial infarction, but this has not been replicated. Vitamin D supplementation has been extensively investigated for cardiac benefit, but no consistent effect has been found. Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). Bisphosphonates could theoretically provide protection against atheroma. However, data from randomised trials and observational studies have neither robustly supported this nor consistently demonstrated the potential association with atrial fibrillation. Denosumab does not appear to be associated with cardiovascular disease and, although parathyroid hormone analogues are associated with palpitations and dizziness, no association with a defined cardiovascular pathology has been demonstrated. Finally, romosozumab has been shown to have a possible cardiovascular signal, and therefore post-market surveillance of this therapy will be vital.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Matèria:	Adverse effects ; Cardiovascular diseases ; Drug safety ; Osteoporosis
Publicat a:	Drugs, Vol. 80 (july 2020) , p. 1537-1552, ISSN 1179-1950

DOI: 10.1007/s40265-020-01364-2
PMID: 32725307

16 p, 967.2 KB

El registre apareix a les col·leccions:
Articles > Articles publicats